EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide

Sofía Scévola, Jordi Niubó, Pere Domingo iD, Guillermo Verdejo, Adrian Curran, Vicens Diaz-Brito iD, Judith Peñafiel, Juan Tiraboschi, Sandra Morenilla, Benito Garcia, Irene Soriano, Daniel Podzamczer und 1 weitere

The Journal of Infectious Diseases · 2023

DOI: 10.1093/infdis/jiad304 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Sofía Scévola und 12 weiteren Autor:innen. Beteiligte Einrichtung: HIV and STI Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of …. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Spanish Network for AIDS Research, Instituto de Salud Carlos III, Red Temática de Investigación Cooperativa en Sida.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Decay of HIV in seminal plasma (SP) and rectal fluid (RF) has not yet been described for the antiretroviral combination of dolutegravir (DTG) + lamivudine (3TC).

Methods

In this randomized multicenter pilot trial, males who were antiretroviral naive were randomized (2:1) to DTG + 3TC or bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). HIV-1 RNA was measured in blood plasma (BP), SP, and RF at baseline; days 3, 7, 14, and 28; and weeks 12 and 24.

Results

Of 25 individuals enrolled, 24 completed the study (DTG + 3TC, n = 16; BIC/FTC/TAF, n = 8). No significant differences were observed between groups for median decline in HIV-1 RNA from baseline at each time point or median time to achieve HIV-1 RNA <20 copies/mL in BP and SP and <20 copies/swab in RF. HIV-1 RNA decay patterns were compared in individuals receiving DTG + 3TC. Despite significantly higher percentages for changes from baseline in BP, median (IQR) times to HIV-1 RNA suppression were shorter in SP (7 days; 0–8.75) and RF (10.5 days; 3–17.5) than in BP (28 days; 14–84; P < .001).

Conclusions

Comparable HIV-1 RNA decay in BP, SP, and RF was observed between DTG + 3TC and BIC/FTC/TAF. As shown with triple-drug integrase inhibitor–based regimens, rapid HIV-1 RNA suppression in SP and RF is achieved with DTG + 3TC, despite decay patterns differing from those of BP. Clinical Trials Registration EudraCT 2019-004109-28.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsMaleAdultHumansLamivudineSemenHeterocyclic Compounds, 3-RingPyridonesAnti-Retroviral AgentsDrug CombinationsRNA, ViralEmtricitabineDolutegravirAlanineTenofovirAmidesPiperazines

Stichwörter der Autor:innen

antiretroviral therapydolutegravirrectumsemen

Substanzen

LamivudineHeterocyclic Compounds, 3-RingPyridonesAnti-Retroviral AgentsDrug CombinationsRNA, ViralEmtricitabineAnti-HIV AgentsDolutegravirtenofovir alafenamide

Autor:innen und Institutionen

  • HIV and STI Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Department of Microbiology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
  • HIV Unit, Santa Creu i Sant Pau Hospital, Barcelona, Spain.
  • Department of Internal Medicine, Sant Camil Hospital, Sant Pere de Ribes, Barcelona, Spain.
  • Department of Infectious Diseases, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Barcelona, Spain.
  • Department of Infectious Diseases, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain.

ORCID-Profile: Pere Domingo, Vicens Diaz-Brito, Arkaitz Imaz

Förderung

  • Spanish Network for AIDS Research
  • Instituto de Salud Carlos III
  • Red Temática de Investigación Cooperativa en Sida
  • ISCIII Subdirección General de Evaluación
  • European Regional Development Fund

Zitieren

APA

Scévola, S., Niubó, J., Domingo, P., Verdejo, G., Curran, A., Diaz-Brito, V., Peñafiel, J., Tiraboschi, J., Morenilla, S., Garcia, B., Soriano, I., Podzamczer, D., & Imaz, A. (2023). Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad304

Vancouver

Scévola S, Niubó J, Domingo P, Verdejo G, Curran A, Diaz-Brito V, et al. Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad304

BibTeX
@article{Scvola2023,
  author = {Scévola, Sofía and Niubó, Jordi and Domingo, Pere and Verdejo, Guillermo and Curran, Adrian and Diaz-Brito, Vicens and Peñafiel, Judith and Tiraboschi, Juan and Morenilla, Sandra and Garcia, Benito and Soriano, Irene and Podzamczer, Daniel and Imaz, Arkaitz},
  title = {Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  doi = {10.1093/infdis/jiad304}
}
Kostenlos starten →